



Version With Markings to Show Changes Made

18. (Amended) A method for treating a developmental defect or a disease of the eye, said method comprising increasing the FREAC3 biological activity in a mammal diagnosed as having [glaucoma] developmental defect or a disease of the eye.

27. (Amended) The method of claim [19] 22, wherein said number of biologically active FREAC3 molecules is increased by administering to said mammal a composition comprising a wild-type FREAC3 polypeptide and a pharmaceutically acceptable carrier.

28. (Amended) The method of claim [24] 27, wherein said pharmaceutically acceptable carrier is physiological saline.

29. (Amended) The method of claim [24] 27, wherein said composition is delivered by ophthalmic administration.

30. (Amended) The method of claim [24] 27, wherein said composition is delivered by intraorbital administration.

31. (Amended) The method of claim [24] 27, wherein said wild-type FREAC3 polypeptide is substantially pure.

TECH CENTER 1600/2900

JAN 02 2003

RECEIVED

Claims as Pending

18. (Amended) A method for treating a developmental defect or a disease of the eye, said method comprising increasing the FREAC3 biological activity in a mammal diagnosed as having developmental defect or a disease of the eye.

19. The method of claim 18, wherein said disease of the eye is glaucoma.

20. The method of claim 18, wherein said developmental defect of the eye is characterized by anterior segment dysgenesis.

21. The method of claim 18, wherein said developmental defect of the eye is Axenfeld-Reiger Anomaly.

22. The method of claim 18, wherein said method comprises increasing the FREAC3 biological activity by increasing the number of biologically active FREAC3 molecules in said mammal.

27. (Amended) The method of claim 22, wherein said number of biologically active FREAC3 molecules is increased by administering to said mammal a composition comprising a wild-type FREAC3 polypeptide and a pharmaceutically acceptable carrier.

28. (Amended) The method of claim 27, wherein said pharmaceutically acceptable carrier is physiological saline.

29. (Amended) The method of claim 27, wherein said composition is delivered by ophthalmic administration.

30. (Amended) The method of claim 27, wherein said composition is delivered by intraorbital administration.

31. (Amended) The method of claim 27, wherein said wild-type FREAC3 polypeptide is substantially pure.

32. The method of claim 18, wherein said mammal is a human.